Progress with human H5N1 vaccines: a perspective from industry

References

• WHO. H5N1 avian influenza: timeline of major events. 11 November 2008.
   Google Scholar
• WHO. Cumulative number of confirmed human cases of avian influenza A/(H5N1) reported to WHO. 11 March 2009.
   Google Scholar
• WHO. Ten things you need to know about pandemic influenza. 14 October 2005.
   Google Scholar
• Biomedical Industry Advisory Group. The Biomedical Research and Development Guide 2006.
   Google Scholar
• International Federation of Pharmaceutical Manufacturers and Associations. Thirty-one avian and pandemic prototype vaccine projects confirm industry’s commitment to deliver influenza solutions. Press release. 1 May 2006.
   Google Scholar
• National Institute of Allergy and Infectious Diseases (NIAID). H5N1 avian flu virus vaccine induces immune responses in healthy adults. Press release. 29 March 2006.
   Google Scholar
• The International Federation of Pharmaceutical Manufacturers and Associations Influenza Vaccine Supply (IFPMA IVS) Task Force. Influenza vaccine distribution in 141 countries, 2004–2007. Presented at: Third European Influenza Conference. Vilamoura, Portugal, 14–17 September 2008.
   Google Scholar
• Hehme N, Engelmann H, Künzel W, Neumeier E, Sänger R. Pandemic preparedness: lessons learnt from H2N2 and H9N2 candidate vaccines. Med Microbiol Immunol191, 203–208 (2002).
   PubMed Web of Science ®Google Scholar
• Sanofi Pasteur. Sanofi Pasteur’s investigational H5N1 influenza vaccine achieves high immune response at low dosage. Press release. 18 September 2007.
   Google Scholar
• Atmar R, Keitel W, Patel S et al. Safety and immunogenicity of non-adjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations. Clin. Infect. Dis.43, 1135–1142 (2006).
   PubMed Web of Science ®Google Scholar
• EMEA. European Medicines Agency receives first pandemic influenza vaccine application. Press release. 6 January 2006.
   Google Scholar
• Sanofi Pasteur. FDA licenses first US vaccine for humans against avian influenza. Press release. 17 April 2007.
   Google Scholar
• Sinovac. Sinovac receives China State Food and Drug Administration (SFDA) approval for pandemic influenza H5N1 vaccine. Press release. 2 April 2008.
   Google Scholar
• CSL. CSL receives TGA approval to register Panvax® avian flu vaccine. Press release. 17 June 2008.
   Google Scholar
• MedImmune. MedImmune licenses reverse genetics technology to Hungary’s Omninvest for influenza vaccine development and production. Press release. 16 October 2008.
   Google Scholar
• WHO. WHO biosafety risk assessment and guidelines for the production and quality control of human influenza pandemic vaccines. WHO technical report series941 (2007).
   Google Scholar
• The Macroepidemiology of Influenza Vaccination (MIV) Study Group. The macroepidemiology of influenza vaccination in 56 countries, 1997–2003. Vaccine23, 5133–5143 (2005).
   PubMed Web of Science ®Google Scholar
• Rodriguez de Azero M; European Vaccine Manufacturers Influenza Working Group. Trends in seasonal influenza vaccine distribution in the European Union: 2003/4–2007/8. Eurosurveillance13(43), 18–21 (2008).
   Google Scholar
• Leroux-Roels I, Borkowski A, Vanwolleghem T et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet370(9587), 544–545 (2007).
   PubMed Web of Science ®Google Scholar
• WHO. Projected supply of pandemic influenza vaccine sharply increases. Press release. 23 October 2007.
   Google Scholar
• Stephenson I, Bugarini R, Nicholson K et al. Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy. J. Infect. Dis.191, 1210–1215 (2005).
   PubMed Web of Science ®Google Scholar
• Ehrlich H, Müller M, Oh H et al. A clinical trial of a whole-virus H5N1 vaccine derived from cell culture. N. Engl. J. Med.358, 2573–2584 (2008).
   PubMed Web of Science ®Google Scholar
• GlaxoSmithKline. New data for GlaxoSmithKline’s pre-pandemic H5N1 influenza vaccine, Prepandrix™, show administration flexibility for pandemic planning. Press release. 16 September 2008.
   Google Scholar
• Novartis. Novartis MF59®-adjuvanted vaccine rapidly induces protective antibody levels against diverse strains of avian flu. Press release. 19 September 2008.
   Google Scholar
• Stephenson I, Nicholson K, Hoschler K et al. Antigenically distinct MF59-adjuvanted vaccine to boost immunity to H5N1. N. Engl. J. Med.359(15), 1631–1633 (2008).
   PubMed Web of Science ®Google Scholar
• Germann T, Kadau K, Longini I, Macken C. Mitigation strategies for pandemic influenza in the United States. Proc. Natl Acad. Sci.103(15), 5935–5940 (2006).
   PubMed Web of Science ®Google Scholar
• Ferguson N, Cummings D, Fraser C et al. Strategies for mitigating an influenza pandemic. Nature442, 448–452 (2006).
   PubMed Web of Science ®Google Scholar
• World Health Assembly resolution. Prevention and control of influenza pandemics and annual epidemics. WHA56.19 (2003).
   Google Scholar
• WHO. WHO global influenza preparedness plan. The role of WHO and recommendations for national measures before and during pandemics. March 2005.
   Google Scholar
• European Centre for Disease Prevention and Control. Report for policymakers: Pandemic preparedness in the European Union. Autumn 2007.
   Google Scholar
• US Department of Health and Human Services and US Department of Homeland Security. Guidance on allocating and targeting pandemic influenza vaccine. July 2008.
   Google Scholar
• Jennings L, Monto A, Chan P, Szucs T, Nicholson K. Stockpiling prepandemic influenza vaccines: a new cornerstone of pandemic preparedness plans. Lancet Inf. Dis.8(10), 650–658 (2008).
   PubMed Web of Science ®Google Scholar
• UK Cabinet Office. National Risk Register (2008).
   Google Scholar
• Netherlands Ministry of Internal Affairs. National Risk Assessment. 30 May 2008.
   Google Scholar